Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Vitiligo - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Vitiligo - Pipeline Insight, 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve Vitiligo.
Vitiligo Emerging Drugs Chapters
This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vitiligo Emerging Drugs
Upadacitinib: AbbVie Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor with seven approved indications and is currently being studied in several immune-mediated diseases.7,8 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.8 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known. Use of upadacitinib in vitiligo is not approved and its safety and efficacy have not been evaluated by regulatory authorities. Currently, the drug is in Phase III stage of its clinical trial for the treatment ofVitiligo.
AMG-714: Amgen AMG-714, a fully human immunoglobulin monoclonal antibody (IgG1?), binds to and inhibits the function of IL-15 in all of its forms (Cis, Trans, and soluble IL-15 bound to IL-15RA), and blocks IL-15-induced T cell proliferation. Currently, the drug is in Phase II stage of its clinical trial for the treatment ofVitiligo.
Vitiligo: Therapeutic Assessment
This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Vitiligo
There are approx. 20+ key companies which are developing the therapies for Vitiligo. The companies which have their Vitiligo drug candidates in the most advanced stage, i.e. Phase III include, AbbVie.
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vitiligo: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.
Key Questions
- How many companies are developing Vitiligo drugs?
- How many Vitiligo drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vitiligo?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vitiligo therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vitiligo and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- AbbVie
- Pfizer
- Incyte Corporation
- Ahammune Biosciences
- Amgen
Key Products
- Upadacitinib
- Ritlecitinib
- Povorcitinib
- AB1001
- AMG-714
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Vitiligo Report Insights
- Vitiligo Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Vitiligo Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/i8qv7q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
